<html><head><style>div {border : red solid 0.5px}</style><style>span {border : blue dotted 0.5px}</style></head><body><div left="34.02" right="50.61" top="760.96"><span x0="34.02" y0="760.96" x1="50.61" style="x0: 34.02; x1: 39.58; y0: 760.96; y1: 770.96; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">35. </span><span x0="55.28" y0="760.96" x1="367.73" style="x0: 55.28; x1: 61.02; y0: 760.96; y1: 770.96; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">This requires both public and private participation and risk sharing</span><span x0="367.78" y0="765.34" x1="374.36" style="x0: 367.78; x1: 371.02; y0: 765.34; y1: 771.17; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">25</span><span x0="374.44" y0="760.96" x1="547.05" style="x0: 374.44; x1: 377.22; y0: 760.96; y1: 770.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. The private sector cannot on its own invest in excess (peak-load) capacity ahead of a pandemic, given the uncertainties over the scale and timing of demand, and over which specific vaccines or other medical countermeasures will meet regulatory approval.</span></div><div left="55.28" right="66.04" top="708.96"><span x0="55.28" y0="708.96" x1="66.04" style="x0: 55.28; x1: 60.47; y0: 708.96; y1: 718.96; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. </span><span x0="69.45" y0="708.96" x1="547.12" style="x0: 69.45; x1: 76.86; y0: 708.96; y1: 718.96; width: 7.41; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">A combination of push incentives (co-funding of R&amp;D and supply capacity) and pull incentives (assured procurements) will be needed </span><span x0="218.99" y0="695.96" x1="547.04" style="x0: 218.99; x1: 224.18; y0: 695.96; y1: 705.96; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">ahead of a pandemic, as well as to accelerate R&amp;D and manufacturing capacity expansion at the beginning of an outbreak.</span></div><div left="69.45" right="546.94" top="656.96"><span x0="69.45" y0="656.96" x1="546.94" style="x0: 69.45; x1: 71.85; y0: 656.96; y1: 666.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. It is more cost-efficient for this to be weighted towards push contracts. They provide the greatest opportunity for securing significant access commitments because of the higher risk involved in the early stages of developing vaccines and other medical countermeasures. </span></div><div left="69.45" right="395.0" top="604.96"><span x0="69.45" y0="604.96" x1="395.0" style="x0: 69.45; x1: 71.85; y0: 604.96; y1: 614.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">ii. There should also be government funding to support the development of </span><span x0="394.37" y0="604.96" x1="541.95" style="x0: 394.37; x1: 400.11; y0: 604.96; y1: 614.96; width: 5.74; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">new manufacturing technologies</span><span x0="541.47" y0="604.96" x1="547.03" style="x0: 541.47; x1: 544.25; y0: 604.96; y1: 614.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">, e.g. for mRNA vaccines and therapeutics to be made on biochips. This has the potential of reducing production costs and human capital requirements, and enabling more ready access to supplies. </span></div><div left="55.27" right="444.13" top="552.96"><span x0="55.27" y0="552.96" x1="444.13" style="x0: 55.27; x1: 61.38; y0: 552.96; y1: 562.96; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. Contractual clauses must incentivize early deliveries and commit firms to quantity, </span><span x0="444.23" y0="552.96" x1="547.15" style="x0: 444.23; x1: 449.6; y0: 552.96; y1: 562.96; width: 5.37; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">adequate allocations to LICs and LMICs, and affordable pricing</span><span x0="269.27" y0="539.96" x1="272.05" style="x0: 269.27; x1: 272.05; y0: 539.96; y1: 549.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">.</span></div><div left="69.44" right="547.03" top="513.96"><span x0="69.44" y0="513.96" x1="547.03" style="x0: 69.44; x1: 71.84; y0: 513.96; y1: 523.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. Government funding in the current pandemic, as well as prior public sector investments in R&amp;D, played an outsized role in the funding of vaccine discoveries for COVID-19. However, these were not structured to fully recognize the public good nature of R&amp;D and such discoveries. </span></div><div left="69.44" right="546.96" top="461.96"><span x0="69.44" y0="461.96" x1="546.96" style="x0: 69.44; x1: 71.84; y0: 461.96; y1: 471.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">ii. Future government funding for medical research should attach clearer conditions if successful discoveries are made, e.g. commitments to provide affordable medical countermeasures with cost-plus pricing for LICs and LMICs, treatment of intellectual property and requirements for technology transfers to third- party manufacturers.</span></div><div left="69.44" right="547.07" top="396.96"><span x0="69.44" y0="396.96" x1="547.07" style="x0: 69.44; x1: 71.84; y0: 396.96; y1: 406.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">iii. There is a critical need for transparency of contracts and in particular, with regard to pricing. The lack of this transparency has militated against developing countries in the current pandemic, with some of them ending up paying more than high-income countries for their vaccines.</span></div><div left="34.0" right="50.78" top="345.36"><span x0="34.0" y0="345.36" x1="50.78" style="x0: 34.0; x1: 39.56; y0: 345.36; y1: 355.36; width: 5.56; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">36. </span><span x0="55.26" y0="345.36" x1="547.21" style="x0: 55.26; x1: 61.56; y0: 345.36; y1: 355.36; width: 6.3; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Black;">Expanding public-private-philanthropic partnerships: We should ensure that this end-to-end ecosystem for global supply of medical countermeasures is tightly networked to significantly scale up production of these supplies</span><span x0="135.24" y0="324.14" x1="141.79" style="x0: 135.24; x1: 138.48; y0: 324.14; y1: 329.97; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">26</span><span x0="141.93" y0="319.76" x1="147.49" style="x0: 141.93; x1: 144.71; y0: 319.76; y1: 329.76; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">. </span></div><div left="55.27" right="547.04" top="294.56"><span x0="55.27" y0="294.56" x1="547.04" style="x0: 55.27; x1: 60.46; y0: 294.56; y1: 304.56; width: 5.19; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">a. We have to leverage comparative strengths across a network of ready-to-act, adequately-funded entities working across different functional areas (from R&amp;D through to manufacturing and procurement)</span><span x0="508.25" y0="286.34" x1="514.8" style="x0: 508.25; x1: 511.49; y0: 286.34; y1: 292.17; width: 3.24; font-size: 5.83; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">27</span><span x0="514.32" y0="281.96" x1="517.1" style="x0: 514.32; x1: 517.1; y0: 281.96; y1: 291.96; width: 2.78; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">.</span></div><div left="55.27" right="547.01" top="256.76"><span x0="55.27" y0="256.76" x1="547.01" style="x0: 55.27; x1: 61.38; y0: 256.76; y1: 266.76; width: 6.11; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">b. ACT-A was an important, ad hoc arrangement during COVID-19, to coordinate efforts to fund and enable equitable access to diagnostics, vaccines, therapeutics and implementation of these in health systems. </span></div><div left="69.44" right="547.0" top="218.96"><span x0="69.44" y0="218.96" x1="547.0" style="x0: 69.44; x1: 71.84; y0: 218.96; y1: 228.96; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">i. Each of the institutions in ACT-A adapted to an evolving situation, and added value through its respective expertise and networks with the private sector and within countries.</span></div><div left="69.44" right="547.06" top="181.16"><span x0="69.44" y0="181.16" x1="547.06" style="x0: 69.44; x1: 71.84; y0: 181.16; y1: 191.16; width: 2.4; font-size: 10.0; fill: [0.137, 0.123, 0.126]; stroke: [0.137, 0.123, 0.126]; font-family: WXJFMZ+AvenirLTStd-Roman;">ii. ACT-A&#8217;s experience also showed the ability of the international community to assemble a coalition of the willing in short order during a major crisis. </span></div><div left="34.02" right="38.63" top="74.7"><span x0="34.02" y0="74.7" x1="38.63" style="x0: 34.02; x1: 36.28; y0: 74.7; y1: 78.78; width: 2.27; font-size: 4.08; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">25</span><span x0="41.11" y0="71.64" x1="220.17" style="x0: 41.11; x1: 45.0; y0: 71.64; y1: 78.64; width: 3.89; font-size: 7.0; fill: [0.137, 0.123, 0.126]; stroke: [0, 0.549, 0.815]; font-family: WXJFMZ+AvenirLTStd-Roman;">https://science.sciencemag.org/content/371/6534/1107</span></div></body></html>